肿瘤细胞治疗研究
英文原题：Advances in CAR-T therapy for small cell lung cancer.
小细胞肺癌 (SCLC) 是一种高度侵袭性的肺癌亚型，治疗选择有限，患者预后差。
小细胞肺癌（SCLC）是高度侵袭性的肺癌亚型，治疗选择有限，患者预后较差。传统治疗包括铂类药物和依托泊苷化疗，虽可带来良好初始应答，但极易出现耐药，导致长期生存率显著降低。近年来，CAR-T 治疗血液系统恶性肿瘤的成功及其治疗实体瘤的潜力，为 SCLC 治疗带来新希望。本文综述 CAR-T 在 SCLC 中的应用，包括 CAR-T 结构优化、SCLC 治疗靶点分析，以及临床前和临床研究最新进展，旨在为 SCLC 免疫治疗提出新见解和创新策略，推动肿瘤免疫治疗领域发展。
Small cell lung cancer (SCLC), a highly aggressive subtype of lung cancer, has limited treatment options and a poor prognosis for patients. Traditional treatments, including platinum-based drugs and etoposide chemotherapy, provide good initial responses but are highly susceptible to drug resistance, resulting in a markedly reduced long-term survival rate. In recent years, the success of chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies and its potential in the treatment of solid tumors have brought new hope for the treatment of SCLC. This article presents a review of the application of CAR-T cell therapy in SCLC, including an examination of the structural optimization of CAR-T cells, an analysis of therapeutic targets for SCLC, and a discussion of the latest progress in preclinical and clinical research. The objective of this study is to present novel insights and pioneering strategies for immunotherapy in SCLC, with the aim of advancing the field of tumor immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
